PAXMAN Launches Neuropathy System After 150-Patient Study

PAXMAN AB launched its Neuropathy System commercially. In a Phase I/II study, 146 of 150 enrolled patients were evaluable; no patients developed Grade 3 or 4 CIPN, and 5.7% required CIPN-related chemotherapy dose modifications.